News stories about Teleflex (NYSE:TFX) have been trending somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Teleflex earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave news articles about the medical technology company an impact score of 47.4865724022406 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Several research firms have issued reports on TFX. ValuEngine cut shares of Teleflex from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Deutsche Bank cut shares of Teleflex from a “buy” rating to a “hold” rating and set a $251.00 price target for the company. in a research report on Tuesday, November 14th. Piper Jaffray Companies initiated coverage on shares of Teleflex in a research report on Friday, November 10th. They issued an “overweight” rating and a $295.00 price target for the company. Morgan Stanley upped their price target on shares of Teleflex from $274.00 to $290.00 and gave the stock an “equal weight” rating in a research report on Friday, November 3rd. Finally, Jefferies Group upped their price target on shares of Teleflex from $270.00 to $295.00 and gave the stock a “buy” rating in a research report on Friday, November 3rd. One research analyst has rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating to the stock. Teleflex presently has a consensus rating of “Hold” and a consensus price target of $274.44.
Teleflex (NYSE TFX) traded up $2.74 during midday trading on Friday, hitting $260.66. 218,200 shares of the company traded hands, compared to its average volume of 229,137. The company has a debt-to-equity ratio of 0.88, a quick ratio of 3.70 and a current ratio of 4.72. The company has a market cap of $11,620.00, a price-to-earnings ratio of 47.05, a PEG ratio of 1.90 and a beta of 1.09. Teleflex has a 1 year low of $162.79 and a 1 year high of $271.23.
Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, November 2nd. The medical technology company reported $2.12 EPS for the quarter, topping the consensus estimate of $2.01 by $0.11. The firm had revenue of $534.70 million during the quarter, compared to analyst estimates of $522.94 million. Teleflex had a net margin of 12.41% and a return on equity of 16.27%. Teleflex’s revenue was up 17.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.80 EPS. analysts anticipate that Teleflex will post 8.36 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, December 15th. Investors of record on Wednesday, November 15th were paid a dividend of $0.34 per share. The ex-dividend date was Tuesday, November 14th. This represents a $1.36 annualized dividend and a dividend yield of 0.52%. Teleflex’s dividend payout ratio (DPR) is presently 24.55%.
In other Teleflex news, CEO Benson Smith sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $258.10, for a total transaction of $516,200.00. Following the transaction, the chief executive officer now owns 76,634 shares in the company, valued at approximately $19,779,235.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Stephen K. M.D. Klasko sold 200 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $265.32, for a total transaction of $53,064.00. Following the transaction, the director now owns 8,080 shares in the company, valued at approximately $2,143,785.60. The disclosure for this sale can be found here. In the last quarter, insiders have sold 2,600 shares of company stock valued at $666,492. 2.39% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Teleflex (NYSE:TFX) Receiving Somewhat Positive Media Coverage, Report Shows” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://ledgergazette.com/2018/01/12/teleflex-tfx-getting-somewhat-favorable-news-coverage-study-finds.html.
Teleflex Company Profile
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.